Q-omics provides the consensus-scored GAS6-DT profile across patient tissues and cancer cell-line models. GAS6-DT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GAS6-DT is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, GAS6-DT RNA expression shows 17,090 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where GAS6-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAS6-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAS6-DT survival associations across molecular data types. GAS6-DT RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAS6-DT RNA expression–survival associations across cancer types. High GAS6-DT expression shows unfavorable associations in BLCA, MESO, KIRP, COAD and UVM, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for GAS6-DT RNA expression.
This table summarizes GAS6-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAS6-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAS6-DT shows lower tumor expression in KIRC, LUAD, BLCA, KIRP and LUSC and higher tumor expression in HNSC. The KIRC box plot shows higher GAS6-DT RNA expression in normal versus tumor tissue (log2 FC = −1.583, t-test p < 0.001).
This table shows molecular features associated with GAS6-DT in patient tissues and cancer cell lines. In patient samples, GAS6-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
